# OnCo record telix (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/telix/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "telix" ;
  schema:name "Telix Pharmaceuticals"@en ;
  schema:description "Telix is the Australian theranostics company behind Illuccix and Gozellix PSMA imaging and a broad therapeutic pipeline; in September 2026 it agreed to buy ITM, the lutetium-177 supplier, a deal not yet closed."@en ;
  schema:url <https://onco.cc/companies/telix/>, <https://telixpharma.com> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://telixpharma.com>, <https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/breaking-news-767/>, <https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/telix-6ktelixanditmjoinfor.htm>, <https://www.sec.gov/Archives/edgar/data/2007191/000162828026061892/telix-6kpixclarafdaapproval.htm>, <https://www.sec.gov/Archives/edgar/data/2007191/000200719125000013/rls6k.htm> ;
  schema:addressCountry "AU" ;
  onco:sections <https://onco.cc/fronts/radiopharma/>, <https://onco.cc/fronts/imaging/> ;
  onco:targets <https://onco.cc/targets/psma/> ;
  onco:drugs <https://onco.cc/drugs/girentuximab-zr89/> ;
  onco:companies <https://onco.cc/companies/itm/> ;
  onco:trials <https://onco.cc/trials/nct07100730/>, <https://onco.cc/trials/nct06520345/>, <https://onco.cc/trials/nct07052214/> .